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Background: To evaluate the utility of home spirometry (HS) versus office spirometry (OS) in
assessing treatment response to azithromycin in bronchiolitis obliterans syndrome (BOS).
Methods: 239 Lung transplant recipients were retrospectively studied. DFEV1  10% from FEV1
at azithromycin initiation for 7 consecutive days in HS or 2 measures in OS were taken as
cut-off for response or progression.
Results: Based upon HS, 161/239 (67%) patients were progressive despite macrolide, 19 of who
exhibited transient improvement in FEV1 (11%). Time to progression was 29 (13e96) days
earlier with HS than in OS. Forty-six (19%) recipients responded in HS after median 81 (22
e343) days, whilst 22% remained stable. Concordance in azithromycin treatment response be-
tween OS and HS was observed in 210 of 239 patients (88%). Response or stabilization conferred
significant improvement in survival (p Z 0.005). Transient azithromycin responders demon-
strated improved survival when compared to azithromycin refractory patients (p Z 0.034).
Conclusions: HS identified azithromycin refractory patients significantly earlier than OS,
possibly facilitating aggressive treatment escalation that may improve long-term outcome.avage; BOS, bronchiolitis obliterans syndrome; FEV1, forced expiratory volume in one 1 s; HS, home
LTx, lung transplantation; OS, office spirometry; RAS, restrictive allograft syndrome.
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406 C. de Wall et al.Treatment response to azithromycin should be assessed 4 weeks after initiation. Responders
demonstrated best survival, with even transient response conferring benefit. Macrolide-
refractory BOS carried the worst prognosis.
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Lung transplantation (LTx) has become an accepted ther-
apeutic option for selected patients with end-stage lung
disease. Post-transplant survival continues to improve, but
mean 5-year survival remains disappointingly low at 53%
[1]. Bronchiolitis obliterans syndrome (BOS) remains the
leading cause of death beyond the first year after trans-
plantation [1], affecting almost half of all patients within 5
years. BOS is characterized by its unpredictable and vari-
able clinical course, ranging from an insidious onset with
gradual loss of pulmonary function over months to years, to
an abrupt and severe decline in pulmonary function within
a matter of weeks [2e4]. Whilst obliterative bronchiolitis is
the presumed histopathological correlate, it is not consis-
tently detectable by transbronchial biopsy and spirometry
is routinely used as the agreed surrogate marker to di-
agnose and stage BOS [5]. Current treatment strategies for
BOS include aggressive management of known risk factors
as well as early identification of BOS and initiation of pro-
posed treatments or re-transplantation.
Long-term azithromycin has been shown to improve FEV1
and survival in up to 40% of BOS patients in various single-
center studies [6e10]. Current data however, does not
provide insight beyond initial response, with little being
known about whether initial responders relapse later or
whether non-responders stabilize after azithromycin initi-
ation. Early azithromycin initiation prior to development of
BOS stage 2 has been associated with a significant reduction
in risk of death [9], suggesting the possibility of critical
therapeutic windows for efficacy of some treatment
options.
Given these issues, prompt assessment for therapeutic
response with a view to treatment escalation in progressive
patients is vital. Previous studies involving lung transplant
recipients have demonstrated the benefits of daily home
spirometry (HS) in detecting early changes in graft function
[11e16]. In the current study, home spirometry data was
used to evaluate treatment response after commencing
azithromycin in LTx patients with BOS to evaluate if
macrolide-refractory progression could be identified earlier
than the present system of office spirometry (OS).Materials and methods
A single-center retrospective analysis of all adult lung
transplant recipients between 2003 and 2011 commenced
on long-term azithromycin for bronchiolitis obliterans was
performed.
Only patients with adequate adherence to home
spirometry (50% prescribed measures) and at least one
follow-up visit after azithromycin initiation were included.
Recipients with severe airway complications, unknown startor interrupted azithromycin treatment were excluded
(Fig. 1). All patients were followed-up from azithromycin
initiation until death, re-transplantation or to completion
of the study on May 31, 2011.Home spirometry (HS)
Patients were instructed on using a home spirometry device
and asked to perform daily testing, ensuring that attempts
were made at the same time each day. All patients used a
handheld electronic spirometry system (VIASYS Health-
care, Hoechberg, Germany) that collected and stored
relevant expiratory flowevolume parameters including
FEV1. Following each attempt, a digital display on the
spirometer indicated the current FEV1 value along with a
direct comparison to the patient’s pre-programmed best
FEV1. Based on a “traffic light” system, the device displays
green when 90% best FEV1 is achieved, yellow for <90%
but 80% and red for <80% best FEV1. The device stores up
to 450 measurements, which were routinely downloaded at
each outpatient attendance and stored centrally in an
electronic database. Patients were instructed to contact
the transplant center within 24 h following a change in
“colour” on the spirometer, regardless of symptoms.Routine follow-up
Patients were followed-up at our specialized outpatient
clinic with scheduled visits at 2- to 4- month intervals.
Standard immunosuppression consisted of a triple-drug
regimen including a calcineurin-inhibitor, prednisolone
and either a cell-cycle-inhibitor or mTOR (mammalian
target of rapamycin) inhibitor. After excluding alternate
causes, azithromycin (as the standard neo-macrolide ther-
apy) was commenced in all patients demonstrating a
persistent deterioration in lung function below 80% base-
line, with most patients receiving an initial loading dose of
500 mg daily for 3 days before continuing with 250 mg three
times per week thereafter. Routine follow-up attendances
included clinical examination, spirometry, capillary blood
gas analysis and a chest x-ray. Bronchoscopy was routinely
performed, based on interpretation of these findings to
investigate suspected rejection, infection or airway
complication.
BOS staging complied with the International Society of
Heart and Lung Transplantation classification of bronchio-
litis obliterans syndrome (BOS) [17]. Baseline FEV1 was
defined as the average of the two highest measurements
obtained at least 3 weeks apart during postoperative
course.
Restrictive allograft syndrome (RAS) was defined ac-
cording to Sato et al. [18]. If TLC data were not available,
RAS was defined by imaging (presence of parenchymal
Figure 1 Enrollement of Patients with azithromycin treatment for bronchiolitis obliterans syndrome (2003e2011). Treatment
response based upon HS.
Home spirometry in lung transplant recipients on azithromycin 407infiltrates) and the absence of an obstructive pattern in
pulmonary function test (FEV/FVC > 0.7).
Interpretation of macrolide response
In home spirometry (HS), patients demonstrating a 10%
FEV1 increase (compared to FEV1 at start of azithromycin)
from the baseline value over a period of 7 consecutive days
were termed responders. Patients with a 10% FEV1 loss
over 7 consecutive days were classified as progressive. All
remaining patients with FEV1 values between 91 and 109%
were considered stabilized. Patients who initially fulfilled
the responder criteria, but subsequently progressed to
90% FEV1 during follow-up, were termed transient
responders.
With regard to office spirometry (OS), the same cut-off
values in %FEV1 were used and considered relevant when
arising in at least two consecutive OS measurements after
excluding alternative causes. OS was performed in accor-
dance to the published guidelines of the American Thoracic
Society and European Respiratory Society [19].
The date of progression or response in HS and OS was
defined as the first occasion on which the cut-off values
were reached.
Statistical analysis
Data are reported as medians with interquartile ranges
(IQR) and all reported p values are two-sided unless
otherwise stated. For all analyses, p-values <0.05 were
considered statistically significant. Category variables were
analysed using either a chi-squared test or Fisher’s exact
test. Medians were compared using the ManneWhitney test
and the nonparametric KruskaleWallis-H test. Cohen’s
kappa coefficient was used as a measure of agreement for
categorical items. Survival curves were constructed using
Kaplan Meier method and compared using the log-rank test.Results
Two hundred thirty-nine lung transplant recipients fulfilled
inclusion criteria. Baseline characteristics of patients are
listed in Table 1. Median follow-up was 22 (11e37) months.
Median FEV1 at azithromycin initiation was 67% (54e77)
baseline, 21% had a restrictive phenotype. Sixty-seven
percent of patients (161/239) demonstrated progression
in HS. Nineteen patients (19/239, 8%) had an initial
response but progressed during follow-up after 501
(232e1334) days and were considered transient responders.
No transient responder stabilized. Time to progression was
61 (24e149) days according to HS and 90 (37e245) days
according to OS. HS detected progression on average 29
(13e96) days earlier than outpatient measures. Median loss
of FEV1 in all progressive patients was 0.4 L (17%) at the
first visit defining progress in OS.
Nineteen percent of patients (46/239) responded to
azithromycin after 81 (22e343) days on HS, compared to
222 (64e551) days on OS. HS detected treatment response
on average 141 (42e208) days earlier than office measures.
Twenty-two percent of patients (51/239) exhibited stabi-
lized lung function after commencing macrolides. Classifi-
cation of azithromycin response was concordant between
HS and OS in 210/239 (88%) patients (Fig. 2).
Seven of 29 patients exhibiting disconcordance between
HS an OS, demonstrated transient responses in HS. Of the
remaining 22 patients, 5 were progressive and 17 were non-
progressive.
Sensitivity and specifity of HS in detecting progressive
patients resulted in p values of 0.800 and 0.962 respec-
tively. Positive predictive value (PPV) and negative pre-
dictive value (NPV) were p Z 0.863 and p Z 0.941.
Sensitivity and specifity of HS in detecting responder
resulted in p values of 0.833 and 0.944 respectively. Posi-
tive predictive value (PPV) and negative predictive value
(NPV) were p Z 0.761 and p Z 0.964. Analysis of concor-
dance between home and clinic spirometry resulted in K
Table 1 Baseline characteristics of patients.
All patients
N 239
Age Years 52 (39e59)
Female gender N (%) 121 (51)
Underlying disease
Emphysema 96 (40)
Pulmonary Fibrosis 48 (20)
Cystic fibrosis 50 (21)
Eisenmenger 28 (12)
Other 17 (7)
Transplant procedure N (%)
Double lung 184 (77)
Single lung 41 (17)
Heart lung 14 (6)
Calcineur-ininhibitor N (%)
Cyclosporine 126 (53)
Tacrolimus 113 (47)
Time between transplantation and inclusion Months 39 (18e68)
BOS stage at start of azithromycin N (%)
0p 37 (15)
1 97 (41)
2 62 (26)
3 43 (18)
FEV1 at start of azithromycin % Baseline 67 (54e77)
Baseline FEV1 % Predicted 85 (68e100)
Restrictive pattern N (%) 49 (21)
BOS onset post-transplant Months 34 (16e58)
Airway colonizationa N (%) 71 (30)
Follow-up after start of azithromycin Months 22 (11e37)
Rapid decliner before azithromycin
(FEV1 decline  100 ml/month)
N (%) 108 (45)
Death during follow-up N (%) 70 (29)
Causes of death N (%)
- Respiratory failure 41 (59)
- Malignancy 5 (7)
- Cardiovascular disease 5 (7)
- Other 19 (27)
Re-transplantation during follow-up N (%) 13 (5)
Median (Interquartile Range).
a Airway colonization with gram-negative bacteria (e.g. Pseudomonas aeruginosa).
408 C. de Wall et al.values of 0.782 for progressive patients. K values for stable
patients and responder indicated substantial agreement
(k Z 0.782, k Z 0.749).
Seventy patients (29%) died during follow-up after 490
(258e1013) days, 59 (84%) in the HS-progressive group.
Causes of death are shown in Table 1. Five of 239 (2%) pa-
tients died from cardiovascular events (stroke n Z 1, ST-
elevation myocardial infarction n Z 1, sudden cardiac
death n Z 3). All patients dying following cardiac arrest
had advanced chronic allograft dysfunction and were oxy-
gen dependent. Thirteen patients (5%) underwent re-
transplantation, all of whom had been HS-progressive. In
HS-progressive patients, 44 (75%) died from respiratory
failure after 450 (215e989) days.
Median survival of all patients was 1952 (1228e3289)
days after transplantation, 756 (379e1302) days after BOSonset and 673 (341e-1106) days after commencing azi-
thromycin. KaplaneMeier survival estimates at 1 and 3
years after initiation of azithromycin was 91% and 74% for
responders versus 69% and 41% for non-responders
(p Z 0.005). Overall survival of progressive and non-
progressive patients is displayed Fig. 3.
Worst survival occurred in the HS-progressive group with
median survival of 1.0 (0.0e2.0) years. Transient azi-
thromycin responders in HS demonstrated improved sur-
vival when compared to azithromycin -refractory patients
(2.0; IQR1.0e4.0) years, p Z 0.034).
BOS onset of BOS was earlier in the progressive group,
arising 31 (15e48) months post-transplant compared to 46
(22e73) months amongst non-progressive patients
(p < 0.05). FEV1 at azithromycin initiation was also lower
65% Best FEV1 (IQR 51e75) vs. 70% (69e79) in the non-
Figure 2 Comparison of home spirometry (HS) and office
spirometry (OS) measurements.
Home spirometry in lung transplant recipients on azithromycin 409progressive group (p < 0.05). No significant differences
were observed in co-medication (steroid pulse or taper,
anti-reflux or pro-kinetic treatments), use of azithromycin
loading dose or gram-negative airway colonization between
the response groups (Table 2).Figure 3 Survival after azithromycin initDiscussion
We describe the utility of home spirometry (HS) in the early
detection of macrolide-refractory BOS. HS identified pro-
gressive patients more than 4 weeks earlier than office
spirometry, whilst achieving acceptable concordance with
office spirometry in assessment of macrolide treatment
response. Home spirometry has previously been validated
in lung transplant populations, with various studies
describing benefits in detecting early changes in graft
function [11e16]. In a study involving 45 LTx recipients,
Finkelstein et al. diagnosed BOS 1 on average 341 days
earlier than OS, with those progressing to BOS 2 and 3 being
identified 144 days earlier [15]. Our findings confirm high
levels of concordance between home spirometry (HS) and
office spirometry (OS).
Despite these findings, we continue to support control-
ling OS 4 weeks after azithromycin initiation due to inad-
equate HS adherence in some patients. Difficulties in
performing the forced expiratory maneuver were suspected
in 60% of patients showing greater variability in HS mea-
surements. Although patients were trained in using the
home spirometer, the measurements were performed un-
supervised, in contrast to OS which was supervised by
experienced personnel, allowing direct correction of false
technique.
In two thirds of observed discrepancies, trends in pul-
monary function were not detected in HS. Additional
training on how to perform HS when recipients are being
prepared for hospital discharge may improve patient
adherence and further improve concordance between HS
and OS. We have previously observed greatest adherenceiation in BOS (office spirometry data).
Table 2 Characteristics of progressive and non-progressive patients based on home spirometry data.
Progressive patients Non-progressive
patients
p-Value
N (%) 161 (67) 78 (33)
Age Years 51 (38e58) 53 (43e61) 0.039
Gender female N (%) 81 (50) 40 (51) 0.888
Cystic fibrosis N (%) 37 (23) 13 (17) 0.261
Gram-negative airway colonization N (%) 48 (30) 23 (30) 0.959
Time between transplantation and initiation Months 35 (18e64) 43 (19e75) 0.253
Time since onset of BOS Months 31 (15e48) 46 (22e73) 0.008
BOS stage at inclusion N (%)
0p or 1 84 (52) 50 (64) 0.082
2 or 3 77 (48) 28 (36)
Baseline FEV1 % Best 65 (51e75) 70 (60e79) 0.032
Use of proton pump inhibitor
or H2 receptor blocker
N (%) 141 (88) 66 (85) 0.529
Azithromycin loading dose N (%) 55 (34) 26 (33) 0.899
Follow-up after start of azithromycin Months 22 (10e37) 23 (12e36) 0.606
Re-transplantation during follow-up N (%) 13 (8) 0 (0) 0.010
Death during follow-up N (%) 59 (37) 11 (14) <0.001
Median (interquartile range).
Bold values represent that values are statistically significant.
410 C. de Wall et al.rates with HS in the initial year following transplantation,
with a subsequent decrease over time [20]. Annual training
updates, reiterating the importance and technique of HS
may improve adherence in long-term transplant recipients.
Less than 5% of patients were identified as transient
responders or stable in HS, while OS demonstrated pro-
gression. It is unsurprising that OS proved less sensitive in
identifying transient responders. Temporary improvements
in pulmonary function occurring between visits could be
potentially missed, in contrast to daily measurements in
HS. In half of transient responders, increases in HS FEV1
appeared implausible, suggesting alternative explanations
including that another person may have performed HS on
the device.
According to various reports, approximately 35% of pa-
tients in different BOS stages respond to macrolide treat-
ment [6,7,21e25]. There exists however no uniform
definition of response, and most studies made no distinc-
tion between long-term and transient response. Our
response rates appear lower and a greater proportion
treatment initiation in advanced BOS stages (2 or 3)
compared to the largest study [8].
Azithromycin was prescribed at 250 mg orally three
times per week, in concordance with the majority of pub-
lished studies [6,8,21,22], including our own experiences
[25]. Very high tissue concentrations, high lipid solubility in
combination with a long half-time allow such treatment
protocols. To optimize patient adherence we recommended
fixed-dosing (MondayeWednesdayeFriday) rather than
alternate days. Current experience in CF-populations has
demonstrated, that if 250 mg is not effective, higher doses
are also generally ineffective and resulted in increased
side-effects [20]. Commonest side-effects included nausea,
vomiting, diarrhea or abdominal pain. Gastrointestinal
intolerance was greatest in daily treatment protocols [30].
In our experience, prolonged use of azithromycin is welltolerated, with at most mild side-effects. No ventricular
arrhythmias were observed in our cohort. This may be
explained by LTx recipients being typically younger, with
proven absence of cardiac disease in contrast to elderly
patients with cardiovascular risk factors [31]. Nevertheless
5/239 (2%) patients died from cardiovascular events (stroke
n Z 1, ST-elevation myocardial infarction n Z 1, sudden
cardiac death n Z 3). Currently we recommend QTc
monitoring prior to initiation and regularly during long-term
azithromycin along with avoidance of other QTc prolonging
drugs.
In accordance with previous studies, macrolide re-
sponders demonstrate significantly better overall survival
compared to non-responders [8,9]. Interestingly, survival in
patients exhibiting a sustained response was similar to
those demonstrating a transient response and non-response
with stable FEV1. This may reflect a more benign disease
course. Our findings emphasize that even short-term
response and stabilization confer patient benefit.
Improved functional reserve afforded by short-term
response and lung function stabilization may facilitate a
more favorable BOS course. In macrolide-refractory pa-
tients alternative treatments such as extracorporeal pho-
topheresis [26], total lymphoid irradiation [27],
montelukast [28], anti-reflux treatment or re-
transplantation remain possible treatment options.
Regarding additional clinical risk factors such as gram-
negative airway colonization or co-medication, no signifi-
cant differences between progressive and non-progressive
patients were observed.
Additional factors may limit the conclusions beyond the
retrospective single-center nature of the study. Bias may
exist in patient adherence due to selection criteria (pa-
tients without HS and non-adherent patients were not
evaluated). Addition of further BOS treatment options
following macrolide initiation such as extracorporeal
Home spirometry in lung transplant recipients on azithromycin 411photopheresis [26], total lymphoid irradiation [27] or
montelukast [28] were not considered.
In conclusion, HS appears to be a safe and reliable tool in
facilitating assessment of treatment response in patients
with BOS commenced on azithromycin. HS detects
macrolide-refractory BOS significantly earlier and might
help optimize treatment escalation through other available
treatments or consideration for re-transplantation. Pa-
tients may be instructed to contact their transplant center
when a significant decline in FEV1 is evident on their HS
device. Changes in HS should then be confirmed by OS.
When long-term use of macrolides is indicated, we recom-
mend outpatient reassessment of treatment response 4
weeks after treatment initiation. Patients with progressive
lung function decline detected by OS or HS despite azi-
thromycin therapy should be considered for early escala-
tion of BOS therapy. It remains conceivable, that
azithromycin also confers a more favorable BOS clinical
course in these patients. Given that BOS is life-threatening,
with no superior alternative treatment, we routinely
continue long-term azithromycin in patients who stabilize
and even in progressive patients if well tolerated. In gen-
eral, patients decline treatment cessation due to anxiety of
further acceleration in FEV1 decline.Authorship
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